Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon β

Identifying effective treatment combinations for MS patients failing standard therapy is an important goal. We report the results of a phase II open label baseline-to-treatment trial of a humanized monoclonal antibody against CD25 (daclizumab) in 10 multiple sclerosis patients with incomplete respon...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Bielekova, Bibiana, Richert, Nancy, Howard, Thomas, Blevins, Gregg, Markovic-Plese, Silva, McCartin, Jennifer, Würfel, Jens, Ohayon, Joan, Waldmann, Thomas A., McFarland, Henry F., Martin, Roland
Médium: Artigo
Jazyk:Inglês
Vydáno: National Academy of Sciences 2004
Témata:
Biological Sciences
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC423259/
https://ncbi.nlm.nih.gov/pubmed/15161974
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.0402653101
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky